ClinicalTrials.gg
TerminatedNCT00478595SYMPHONYUpdated Jun 6, 2016

Japanese Study With Rimonabant in Obese Type 2 Diabetic Patients With Oral Anti-diabetic Drug

A Phase 3 interventional study of Rimonabant and Placebo (for Rimonabant) in Obesity and Diabetes Mellitus Type 2, sponsored by Sanofi. Terminated at 1 site in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2016-06-06.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Why this study was terminated
Company decision taken in light of demands by certain national health authorities

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
458
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing rimonabant in Obesity — none open to participants now, none under way, none of them phase 3. Rimonabant · Obesity.

Enrollment
13th of 21
458 · median 643
Started
2007
with 5 others
Phase 3
18 of 21
none open now
Registered
15th of 21
by date
Lead sponsor
19 of 21
Sanofi

Among the 21 studies testing rimonabant in Obesity, this one is the 13th largest by enrollment, is one of 6 that started in 2007, is one of 18 in phase 3, and was the 15th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 21 studies testing rimonabant in Obesity is open now. The open studies under Obesity, anywhere →

About rimonabant

Rimonabant: first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing rimonabant in Obesity as a file.
02

Study summary

The primary objective of this study is to assess the efficacy of Rimonabant (SR141716) compared to placebo on change in HbA1c and on relative change in body weight over 52 weeks in obese type 2 diabetic patients on monotherapy inadequately controlled with oral anti-diabetic drug (sulfonylurea or α-glucosidase inhibitor).

The secondary objectives are:

  • To evaluate the effect of Rimonabant compared to placebo on other parameters related to the glucose control, waist circumference, Body Mass Index and metabolic parameters;
  • To evaluate the safety and tolerability of Rimonabant compared to placebo;
  • To evaluate the pharmacokinetics of Rimonabant.
Read the detailed description

The total duration per patient will be approximately 69 weeks including a 52-week double-blind treatment period.

03

Conditions studied

  • Obesity
  • Diabetes Mellitus Type 2

Keywords

  • obese
  • diabetes
  • cannabinoid-1 receptor
04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 2 Diabetes Mellitus patients on monotherapy with oral anti-diabetic drug (sulfonylurea or α-glucosidase inhibitor)
  • ≥ 7.0 % and ≤ 10.0 %
  • ≥ 25 kg/m²

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes
  • Within 12 weeks prior to screening visit: use of oral antidiabetic drugs (other than a sulfonylurea or alpha-glucosidase inhibitor) and/or insulin, of anti-obesity drugs or other drugs for weight reduction
  • Within 4 weeks prior to screening visit: administration of systemic long-acting or prolonged use (more than one week) of other systemic corticosteroids, change in lipid lowering treatment
  • Secondary obesity
  • Primary hyperlipidemia
  • Positive serum pregnancy test in females of

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
458 participants (actual)

Study arms

  • Experimental
    Rimonabant

    Rimonabant 20 mg once daily

    Drug: Rimonabant · Drug: Anti-diabetic monotherapy

  • Placebo comparator
    Placebo

    Placebo (for Rimonabant) once daily

    Drug: Placebo (for Rimonabant) · Drug: Anti-diabetic monotherapy

Interventions

  • Tablet, oral administration

    Also known as: SR141716, Acomplia

  • DrugPlacebo (for Rimonabant)

    Tablet, oral administration

  • Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period

06

What researchers measure

Primary outcomes

  1. Absolute change from baseline in HbA1C

    Time frame: Baseline to week 52

  2. Relative change from baseline in in body weight

    Time frame: Baseline to week 52

Secondary outcomes

  1. Absolute change from baseline in Fasting Plasma Glucose

    Time frame: Baseline to week 52

  2. Absolute change from baseline in waist circumference

    Time frame: Baseline to week 52

  3. Relative change from baseline in Triglycerides and HDL-cholesterol

    Time frame: Baseline to week 52

  4. Safety: overview of adverse events

    Time frame: Baseline to Week 56

07

Study locations

1 site
  • Sanofi-Aventis Administrative Office
    Tokyo, Japan
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2007
First posted
May 25, 2007
Start
Apr 2007
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Jun 1, 2016
Last update
Jun 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00478595
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 25, 2007
Start date
Apr 2007
Primary completion
Feb 2009
Completion
Feb 2009
Last update
Jun 6, 2016

Study contacts

ICD CSD
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rimonabant

Start the discussion